This is Ohms answer for those who are interested:
Post# of 148298
“ Have to answer by PM, out of posts. I believe leronlimab would replace the function of beta arrestin-1. The difference being arrestin beta -1 would have a feedback mechanism that could limit it's number and effectiveness. With leronlimab it's coverage of CCR5 just depends on the volume of the drug and it's mode of administration (IV or subcutaneous). Leronlimab will act like a super effective arrestin beta -1.
Thanks so much Ohm20!